L-histidine-based pH-sensitive anticancer drug carrier micelle: reconstitution and brief evaluation of its systemic toxicity.

International Journal of Pharmaceutics
Kyung T OhYou Han Bae

Abstract

A doxorubicin (DOX)-carrier micellar system consisting of poly(histidine)(5K)-b-poly(ethylene glycol)(2K) and poly(l-lactic acid)(3K)-b-PEG(2K)-folate has been developed targeting the early endosomal pH and it have been convincingly proved that intracellular high dose strategy using such micelles is effective in overcoming multidrug resistance (MDR) of cancer cells. Due to the low DOX concentrations in the micelle solution obtained by dialysis and the lack of long-term stability of the micelles, stable and lyophilized micelle formulations were the subject of investigation reported here by using excipients of sucrose, PEG or Pluronic. The reconstituted micelle solutions were examined by particle size, pH sensitivity, and cytotoxicity for MDR cells and the results were compared with the non-lyophilized micelles. Among tested excipients, Pluronic F127 (33 wt%) added to the polymer/drug solution prior to dialysis resulted in a reconstituted product stable for a week and presented equivalent benefits as the fresh micelle formulation. The blank micelles did not present any apparent systemic toxicity in mice up to 2400 mg/kg i.v. injection (800 mg/kg day) for 3 days). The brief toxicity of reconstituted DOX loaded micelles was examine...Continue Reading

References

Jan 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E BovenH M Pinedo
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·S M Simon, M Schindler
Mar 20, 1998·Human & Experimental Toxicology·R DuncanS Burtles
Jan 20, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·K BreistølO Fodstad
Oct 26, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·K BreistølO Fodstad
Jan 21, 2000·Journal of Controlled Release : Official Journal of the Controlled Release Society·K KataokaG S Kwon
Mar 17, 2001·Advanced Drug Delivery Reviews·K KataokaY Nagasaki
Mar 19, 2002·Advanced Drug Delivery Reviews·Afsaneh LavasanifarGlen S Kwon
Mar 21, 2002·Nature Reviews. Cancer·Michael M GottesmanSusan E Bates
Jul 26, 2003·Journal of Controlled Release : Official Journal of the Controlled Release Society·Eun Seong LeeYou Han Bae
Aug 23, 2003·Journal of Controlled Release : Official Journal of the Controlled Release Society·Eun Seong LeeYou Han Bae
Oct 31, 2003·Expert Reviews in Molecular Medicine·M Links, R Brown
Jan 28, 2004·Journal of Controlled Release : Official Journal of the Controlled Release Society·Kyung T OhAlexander V Kabanov
Mar 20, 2004·Science·Theresa M Allen, Pieter R Cullis
Mar 15, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Eun Seong LeeYou Han Bae
Aug 30, 2005·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Jian-Cheng WangHow-Sung Lee
Aug 30, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R AdvaniB I Sikic
Nov 22, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Kanjiro MiyataKazunori Kataoka
Mar 7, 2006·Nature Reviews. Drug Discovery·Gergely SzakácsMichael M Gottesman
May 23, 2006·International Journal of Pharmaceutics·Mahesh D ChavanpatilJayanth Panyam
Aug 8, 2006·Journal of Controlled Release : Official Journal of the Controlled Release Society·Refika I PakunluTamara Minko
Aug 15, 2006·International Journal of Pharmaceutics·Wassim AbdelwahedHatem Fessi
Nov 15, 2006·Anti-cancer Agents in Medicinal Chemistry·Theresa M AllenKimberley M Laginha
Sep 11, 2007·Journal of Controlled Release : Official Journal of the Controlled Release Society·Eun Seong LeeYou Han Bae
Sep 25, 2007·International Journal of Pharmaceutics·Fang LiXing Tang

❮ Previous
Next ❯

Citations

Jul 18, 2012·International Journal of Nanomedicine·Lili WangNa Zhang
Mar 13, 2014·International Journal of Molecular Sciences·Li-Xia FengNa Zhang
May 1, 2013·Drug Development and Industrial Pharmacy·Ivan PepićJelena Filipović-Grčić
Mar 15, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Rong LiuZhongwei Gu
Sep 21, 2010·Colloids and Surfaces. B, Biointerfaces·Eun Seong LeeKyung Taek Oh
Mar 25, 2010·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Farhan AlHusbanAfzal R Mohammed
Jun 24, 2008·Journal of Controlled Release : Official Journal of the Controlled Release Society·Eun Seong LeeYou Han Bae
Aug 16, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Ahmed O ElzoghbyNazik A Elgindy
Jul 9, 2016·Colloids and Surfaces. B, Biointerfaces·Chu GongGuolin Wu
Nov 28, 2012·Advanced Healthcare Materials·Yi LiDoo Sung Lee
May 24, 2017·Journal of Materials Science. Materials in Medicine·Pinunta Nittayacharn, Norased Nasongkla
Mar 7, 2014·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Eun Seong LeeKyung Taek Oh
Nov 28, 2012·Advanced Healthcare Materials·Chaoliang HeXuesi Chen
Feb 4, 2010·Langmuir : the ACS Journal of Surfaces and Colloids·Julian ThieleStephan Förster
May 1, 2021·Pharmaceutics·Alex N FrickensteinLacey R McNally

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

© 2022 Meta ULC. All rights reserved